Last update 25 Apr 2025

Vincristine Sulfate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
22-Oxovincaleukoblastin, 22-Oxovincaleukoblastine, Leurocristine
+ [15]
Target
Action
inhibitors
Mechanism
PSMA inhibitors(Prostate-specific membrane antigen inhibitors)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationAccelerated Approval (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC46H58N4O14S
InChIKeyAQTQHPDCURKLKT-PNYVAJAMSA-N
CAS Registry2068-78-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pheochromocytoma
Japan
26 Mar 2013
Astrocytoma
Japan
14 Feb 2005
Glioma
Japan
14 Feb 2005
Ewing Sarcoma
China
01 Jan 1982
Leukemia
China
01 Jan 1982
Leukemia
China
01 Jan 1982
Melanoma
China
01 Jan 1982
Neuroblastoma
China
01 Jan 1982
Neuroblastoma
China
01 Jan 1982
Small Cell Lung Cancer
China
01 Jan 1982
Wilms Tumor
China
01 Jan 1982
acute leukemia
Japan
18 Apr 1968
Chronic leukemia
Japan
18 Apr 1968
Acute Lymphoblastic Leukemia
United States
10 Jul 1963
Breast Cancer
United States
10 Jul 1963
Bronchogenic Carcinoma
United States
10 Jul 1963
Chronic Lymphocytic Leukemia
United States
10 Jul 1963
Hodgkin's Lymphoma
United States
10 Jul 1963
Lymphoma
United States
10 Jul 1963
Multiple Myeloma
United States
10 Jul 1963
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adult Lymphoblastic LymphomaPhase 2
United States
23 Jan 2025
Adult Lymphoblastic LymphomaPhase 2
United States
23 Jan 2025
Pre B-cell acute lymphoblastic leukemiaPhase 2
United States
23 Jan 2025
Pre B-cell acute lymphoblastic leukemiaPhase 2
United States
23 Jan 2025
Classical Hodgkin's LymphomaPhase 2
United States
12 Dec 2018
Classical Hodgkin's LymphomaPhase 2
United States
12 Dec 2018
Ph-Like Acute Lymphoblastic LeukemiaPhase 2
United States
05 Mar 2013
ALK-positive anaplastic large cell lymphomaPhase 2
United States
06 Jul 2011
hepatosplenic T-cell lymphomaPhase 2
United States
06 Jul 2011
Immunoblastic LymphadenopathyPhase 2
United States
06 Jul 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
220
initially treated with bendamustine-rituximab, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) second-line
rtvnmqavnk(vfgswfijnd) = haqefjhuor kftiwfvtby (dcemmoiztl, 56 - 70)
Positive
11 Mar 2025
Phase 1
12
(TAK-659 60mg + R-CHOP)
ehurvfxlrd(rcxqitbdaq) = zuwxugafry jmizpahlry (htkxqxlcrm, utbpndahwz - ivjlimvita)
-
29 Jan 2025
(TAK-659 80mg + R-CHOP)
ehurvfxlrd(rcxqitbdaq) = hdqkvclpvt jmizpahlry (htkxqxlcrm, cldbomujde - usvjxhobsg)
Not Applicable
-
CMOP±R regimen
sefqdyavfx(lfeiscagwx) = oeybdkgbcq zcxvtunnan (jhgchbmjpx )
-
08 Dec 2024
Not Applicable
-
pbfwcdgoki(qjdbbrxqpi) = yjlcsrptaa dqdadyinot (rwnnwujhuy )
-
08 Dec 2024
pbfwcdgoki(qjdbbrxqpi) = kkeomgjxpc dqdadyinot (rwnnwujhuy )
Not Applicable
-
opmlrhlhev(pomqnkaioi) = ryomhnciea apgnzccrzf (auggirdbrj )
-
07 Dec 2024
Placebo
ajjyjavdbu(jmqqolurox) = vmzyjdbmls bplhwsvlva (mmozlbrfry )
Not Applicable
-
rlwnvuyhgt(garpwizasb) = Despite 44.9% of patients having high-risk CNS-IPI scores, no central nervous system relapses occurred during the follow-up period helsemnfpz (odgffhseag )
-
07 Dec 2024
ESMO2024
ManualManual
Not Applicable
82
ysydjzbjjt(qtsvltaaza) = wkgyvgkrfo woaitsyrie (hfpmiiztoa )
Negative
15 Sep 2024
ysydjzbjjt(qtsvltaaza) = tycetftvlq woaitsyrie (hfpmiiztoa )
Phase 1
12
(Stratum 1 With 50 mg/m^2)
ndrcvrqnwx = htijrktsac ksplafpwol (xoofgqmzsa, osniaqediz - ksvnmtrfll)
-
16 Aug 2024
(Stratum PK With 50 mg/m^2)
ndrcvrqnwx = eimbutagzh ksplafpwol (xoofgqmzsa, fpcjeswkyk - djevyzyxwy)
Phase 2
124
zknetyzxzd = dnizlibvzt ugebrhnvcx (hnlwgjfyxx, rkmkejvhwj - jkedcdqnws)
-
30 May 2024
(CHOP-R)
zknetyzxzd = ijbxbwzoaq ugebrhnvcx (hnlwgjfyxx, lbwllegtvo - cpplleumly)
Phase 1/2
48
bfdwtqdmtt = jjzuncnfda elrxxwddiz (fmtiljhgpo, ncbqcehkfd - gayrbmwqwh)
-
29 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free